. Author manuscript; available in PMC: 2022 Oct 1.

Published in final edited form as: J Am Geriatr Soc. 2021 Jun 15;69(10):2811–2820. doi: 10.1111/jgs.17310

Table 2:

Unadjusted 30-day and 1-year^* Mortality Rates after First Hospitalization for HFrEF based on Age and Neurohormonal Therapy Use after Discharge, 2008–2015

	Age 66–74	Age 75–84	Age 85+
30-Day Mortality
*Beta-Blockers*
No Fill within 30d	2289 (6.1)	4739 (8.2)	7147 (12.7)
Fill within 30d	885 (1.9)	1440 (2.5)	1795 (4.3)
Number Needed to Treat (30-day mortality)	24	18	12
*ACEi/ARB/ARNI*
No Fill within 30d	2581 (5.7)	5288 (7.7)	7739 (11.9)
Fill within 30d	593 (1.6)	891 (1.9)	1203 (3.7)
Number Needed to Treat (30-day mortality)	24	17	12

1-Year Mortality ^*	Age 66–74	Age 75–84	Age 85+
*Beta-Blocker Exposure*
No Exposure (0 PDC)	4667 (26.3)	9513 (31.7)	13484 (39.2)
Any Exposure (1+ PDC)	10601 (16.2)	18318 (21.7)	20714 (32.9)
Number Needed to Treat (1-year mortality)	10	10	16
*ACEi/ARB/ARNI Exposure*
No Exposure (0 PDC)	7005 (27.9)	14129 (33.5)	18756 (41.0)
Any Exposure (1+ PDC)	8263 (14.0)	13702 (18.7)	15442 (29.4)
Number Needed to Treat (1-year mortality)	7	7	9

Conditional on survival to 30-days after discharge